Details

Autor(en) / Beteiligte

• Merigan, Thomas C
• Renlund, Dale G
• Keay, Susan
• Bristow, Michael R
• Starnes, Vaughn
• O'Connell, John B
• Resta, Silvia
• Dunn, Diane
• Gamberg, Patricia
• Ratkovec, Ranae M
• Richenbacher, Wayne E
• Millar, Roger C
• DuMond, Charles
• DeAmond, Bernadette
• Sullivan, Veronica
• Cheney, Tricia
• Buhles, William
• Stinson, Edward B

Titel

A Controlled Trial of Ganciclovir to Prevent Cytomegalovirus Disease after Heart Transplantation

Ist Teil von

• The New England journal of medicine, 1992-04, Vol.326 (18), p.1182-1186

Ort / Verlag

Boston, MA: Massachusetts Medical Society

Erscheinungsjahr

1992

Quelle

MEDLINE

Beschreibungen/Notizen

• MANY heart-transplant recipients become infected with cytomegalovirus (CMV) with substantial short-term complications, 1 including both systemic and focal CMV illness in the first months after transplantation as well as increased susceptibility to other opportunistic infections during the first year. 2 CMV gastrointestinal disease and pneumonia are the most important short-term sequelae of CMV infection in heart-transplant recipients. 1 CMV infections have also been associated with a higher incidence of coronary artery disease in the years after transplantation. 3 Ganciclovir treatment produces improvement in the manifestations of disease due to CMV in this and other populations. 4 In addition, ganciclovir was recently found to be useful . . .